ERBB2 and thyroid cancer: To date, many studies have evaluated HER2 expression in thyroid cancer with controversial results, largely due to inter-study differences in the size and setting of the examined series and, most of all, to the subjective assessment and lack of uniform methodology [14,15,16,17,18,19,20,21,22,23,24,25,26].